Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Suzuken CoTSE:9987 -0.18%80 EV-to-EBIT is 3.72 as of Aug. 24, 2026, which is 22% below its 10-year median of 4.77. GuruFocus rates TSE:9987 with a GF Score™ of 80/100 and a GF Value™ of 円5,941.71 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 96 Medical Distribution companies, Suzuken Co ranks better than 92.71% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Suzuken Co's Enterprise Value for the quarter that ended in Mar. 2026 was 円259,896 Mil.
Suzuken Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円53,171 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Suzuken Co EV-to-EBIT Related Terms
Suzuken Co EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Suzuken Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Suzuken Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Suzuken Co EV-to-EBIT vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Suzuken Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Suzuken Co's EV-to-EBIT falls into.
Suzuken Co's current Enterprise Value is 円197,976 Mil.
Suzuken Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円53,171 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Suzuken Co (TSE:9987) has a EV-to-EBIT of 3.72 as of Aug. 24, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Suzuken Co and its competitors. This is 22% below median its historical median of 4.77. Over the past decade, Suzuken Co's EV-to-EBIT has ranged from 0.55 to 13.21. According to the industry distribution chart, Suzuken Co ranks #7 out of 96 companies in the Medical Distribution industry, placing it in the top 7.3%.
Is Suzuken Co's EV-to-EBIT too high?
Suzuken Co's current EV-to-EBIT of 3.72 is 22% below median its 10-year median of 4.77. Over the past 10 years, this metric has ranged from a low of 0.55 to a high of 13.21. The Medical Distribution industry median EV-to-EBIT is 11.71. Suzuken Co's value of 3.72 is 68.2% below this industry median. Based on the distribution chart, Suzuken Co ranks #7 out of 96 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Suzuken Co has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Suzuken Co's EV-to-EBIT compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Suzuken Co ranks #7 out of 96 companies for EV-to-EBIT. This places Suzuken Co in the top 7% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 11.71. Suzuken Co's value of 3.72 is 68.2% below this benchmark. Historically, Suzuken Co's own EV-to-EBIT has ranged from 0.55 to 13.21 over the past decade. While the company's 10-year median is 4.77 vs. the industry median of 11.71, Suzuken Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Distribution company?
The median EV-to-EBIT among Medical Distribution companies is 11.71, based on 96 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Suzuken Co's current EV-to-EBIT of 3.72 is 68.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Suzuken Co and its competitors. For the Medical Distribution industry, the median EV-to-EBIT is 11.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Suzuken Co's current EV-to-EBIT is 3.72, which is 22% below median its own 10-year median of 4.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzuken Co stock overvalued right now?
Based on GuruFocus' analysis, Suzuken Co (TSE:9987) is currently considered Modestly Undervalued. The stock's GF Value™ is 円5,941.71, compared to a current price of 円5,124.00 — trading 13.8% below its estimated fair value. The current EV-to-EBIT is 3.72, which is 22% below median its 10-year median of 4.77 and 68.2% below the Medical Distribution industry median of 11.71. Suzuken Co's overall GF Score™ is 80/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Suzuken Co (TSE:9987), the current EV-to-EBIT is 3.72 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Suzuken Co (TSE:9987) Overvalued in 2026?
Based on GuruFocus' analysis, Suzuken Co stock appears to be undervalued.
The current stock price of 円5,124.00 is trading 13.8% below its estimated GF Value™ of 円5,941.71.
GuruFocus considers Suzuken Co to be Modestly Undervalued.
Key valuation signals for TSE:9987:
EV-to-EBIT: 3.72 (22% below median its 10-year median of 4.77)
GF Value™: 円5,941.71 vs. price of 円5,124.00 (13.8% below fair value)
Industry Position: 68.2% below the Medical Distribution median (#7 of 96)
No single metric tells the full story. See the TSE:9987 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Suzuken Co Ltd is engaged in the manufacture and sale of pharmaceuticals and medical devices, and in providing insurance, pharmacy, and nursing care services. The company operates through segments, including Pharmaceutical Wholesale business, Healthcare product development business, Specialty Pharmaceuticals Distribution business, Regional medical nursing care support business, and Medical-related Services business. It generates the majority of its revenue from the Pharmaceutical Wholesale Business segment, which sells prescription pharmaceuticals, diagnostic reagents, medical equipment, and medical supplies.
80GF Score
Get the complete analysis for TSE:9987
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:9987 has been successfully added to your 
